COVID-19 Facilitator Guide December 1 2022

Federal Democratic
Republic of Ethiopia
Ministry of Health
Covid-19 Vaccination Training
Facilitator Manual
October, 2022
Table of Contents
Acknowledgment I
List of Abbreviations II
Forward III
About the Manual IV
Course Syllabus V
Sess
Session I
Basic Fact about the Pandemic 1
Session II
Rationale and Objective for COVID-19 Vaccine 4
Session III
COVID-19 Vaccine supply chain and waste management 5
Session IV
Adverse Events following immunization (AEFI) Surveillance 10
Session V
Demand Generation/ Promotion & Risk Communication 14
Session VI
Coordination and Planning for COVID-19 Vaccine 18
Session VII
Vaccine Delivery Strategies 20
Session VIII
Monitoring and evaluation of COVID-19 Vaccination. 21 22
ANNEX
Course Assessment Questions 29

Acknowledgement
The Federal Ministry of Health would like to sincerely thank all individuals and organizations
who have contributed to the revision of the COVID-19 vaccine training manual and field guide.
This revised manual and field guide is the result of teamwork between FMOH, EPHI, EFDA, EPSA,
WHO, UNICEF, USAID, CHAI, JSI-UI-FHS, GHSC-PSM, BMGF, TBI, and CDC who are committed to
improving immunization services in Ethiopia.
Participant Manual Development Team Members
Dr.Meseret Zelalem MOH Mr. Belete Alebachew MOH
Mr.Yohannes Lakew MOH Mr. Kibrom Abraham MOH
Mr.Temesgen Lemma MOH Dr. Meheret Elias MOH
Mr.Melkamu Ayalew MOH Mr. Mulat Nigus MOH
Mrs.Tewabech Alemu MOH Mr. Yosef Tariku MOH
Mr.Habtamu Alemay MOH Mr. Mengistu Bogale MOH
Mr.Sileshi Solomon MOH Mr.Meseret Adugna PPMED/MOH
Mr.Michael Sileshi MOH Mr. Agumas Kindu EPSS
Mrs.Mastewal Kerebih MOH Dr.Abayneh Girma WHO
Dr.Alemayehu Ayele MOH Mrs.Alemtsehay Berhanu GHSC_PSM
Mrs.Nafkot Abadura MOH Dr.Tedi Tilahun WHO/EFDA
Mrs.Tseganesh Gedlu MOH Dr.Adamu Gelaw WHO/EPHI
Mr.Girma Hailemariam MOH Mr.Haimanot Fisseha UNICEF
Mr.Tesfaye Bikes MOH Mrs.Selamawit Yilma WHO
Dr.Zufan Abera MOH Mr.Wondimu Ayana WHO
Mr.Tekalign Admasu MOH Mrs.Tadelech Sinamo JSI immunization
Mr.Mengesha Belay MOH Mr.Haile Kasahun AACARHB/CHAI
Mr.Jiregna Wirtu MOH Dr.Kume Alene CHAI
Mr.Biruh Tesfaye MOH Dr.Amare Bayeh PATH
Mrs.Bezawit Getachew MOH Mrs.Bethelhem Assefa MOH
Mrs.Mekdim Hailu MOH
I COVID-19 Vaccination Training

Participant Manual
LIST OF ABBREVIATIONS
AEFI Adverse events following immunization
COVID-19 Coronavirus disease 2019
CSO Civic service Organization
DHIS2 District Health Information System
EUL Emergency Use Listing
FMOH Federal Ministry of Health
FBO Faith-Based organization
SAGE Strategic Advisory Group of Experts
SARS-COV-2 Severe Acute Respiratory Syndrome Coronavirus 2
WHO World Health Organization
COVID-19 Vaccination Training

II Facilitator Guide
FOREWARD
The most recently discovered coronavirus, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), causes coronavirus disease 2019 (COVID-19). COVID-19 was unknown prior to the
outbreak in Wuhan, China, in December 2019, but is now a pandemic affecting most countries
globally.
The Government, in collaboration with partners, has maximized its efforts in response to the
COVID-19 pandemic: including intensified case search; investigation and lab testing;
establishing quarantine centers; establishing and expansion of COVID-19 treatment centers
and diagnostic facilities; enforcement of COVID-19 prevention, and infection prevention and
control (IPC) measures.
As a continued effort, the Ministry of Health has planned to introduce COVID-19 vaccine with
the objective to reduce morbidity and mortality from the COVID-19 disease and minimize the
overall negative impacts of the pandemic on health, social and economic wellbeing of the
people of Ethiopia. Synchronized COVID-19 vaccination was launched on 13th of March 2021
nationwide in the presence of national and sub-national political leaders, religious leaders,
other influential public figures and partner organization representatives.
Due to concern of limited supply of vaccine for the entire population, Ethiopia has followed
SAGE’s roadmap and country SARS CoV-2 epidemiology for prioritization of target populations
to identify most at risk and prioritize them for the COVID-19 vaccination. As the vaccine supply
increased significantly the need for target shifting was made and all people aged 12 years and
above are the target populations for COVID-19 vaccination.
Therefore, the MOH, in collaboration with partners, has revised this training manual
accommodating and including latest WHO emergency use list vaccines (EUL) and those which
will be available in the global market that will be used as a guide to train and enable health
professionals who will be involved during the COVID 19 vaccination to acquire and stay
updated with the necessary knowledge, attitudes, and skills for the successful delivery of the
COVID-19 vaccines.
Dr Meseret Zelalem Tadesse (MD, Pediatrician)

Director of the Maternal and Child Health Directorate at FMOH

III Facilitator Guide
About the manual
■ This manual is intended to guide and update health professionals, EPI experts, and partners
on each WHO-approved COVID-19 vaccine

■ The manual is built upon existing documents and the core principles of the WHO Strategic
Advisory Group of Experts (SAGE) values framework for the allocation and prioritization of
COVID-19 vaccination, SAGE interim vaccine-specific recommendations, and COVID-19 vaccine
explainer
■ Due to the constantly changing environment for COVID-19 vaccine development, the guidance
is based upon the best available and updated information at the time of publication. These
assumptions will require updating over time due to the evolving situation
■ This manual included all WHO Emergency Use listing vaccines, procured, and distributed
through the COVAX facility and vaccines on bilateral donation

■ In this manual, the upcoming lists of vaccines under review are highlighted
The manual consists of 8 sections covering key thematic areas and it can be updated whenever
there is a new development.
IV
Course Syllabus
Course These 2 days of training are designed to equip trainees with appropriate knowledge,
Description skill, and attitude to EPI managers and service-providing health workers regarding
COVID-19 vaccines.
Course To transfer knowledge, skills and attitude to EPI managers and health workers on
Goal COVID-19 vaccines and enable them to provide better immunization services to
the community.
Participants After completing this course participants will be able to:

Learning ■ Describe the covid-19 mode of transmission, clinical features,
Objective epidemiological background, and prevention and control of the
disease pandemic.
■ Describe facts on the rationale and objectives of the COVID-19 vaccine
introduction in Ethiopia.
■ Describe the effective communication methods, demand promotion
strategies and activities, and the communication process for successful

COVID-19 vaccine introduction and implementation.
■ Explain basic concepts on targeting and prioritization of risk groups for
COVID-19 vaccination and explain service delivery strategies as well as

the organization of vaccination sessions.
■ Describes concepts on Adverse Events Following Immunization (AEFIs)
monitoring to enable the participants to acquire the necessary

knowledge and skills to monitor and manage AEFIs.
■ Describes the current global development on COVID-19 vaccines, WHO
EUL vaccines, forecasting and procurement, vaccine storage, handling,

cold chain management, and stock management.
■ Describes the necessary coordination mechanisms and planning
process for COVID-19 vaccine introduction

■ Describes the importance of monitoring and evaluation during the
COVID-19 vaccine introduction

■ Describes the roles and responsibilities of the major stakeholders
involved during the COVID-19 vaccine at all levels.

V Facilitator Guide
Describes the role of health workers in COVID-19 surveillance and acquires the
necessary knowledge, skill, and attitude of basic surveillance strategies and
methods to support active case search, contact tracing, alert investigation, and
screening effectively.
Training ■ Interactive PowerPoint presentation

Method ■ Group-based learning: Group work, Exercises, Brainstorming,
Plenary discussion
■ Case study, case scenario
■ Demonstration (session organization, vaccine administration,

recording and documentation)
■ Reading
Training ■ Printed materials: participant manual, facilitator guide, Powerpoint

■ Non- projected materials: Flip chart, writing board, marker
Material
■ Projected materials: LCD, Laptop computer
■ Stationary materials: Notebooks, pens, papers, Flipcharts, and markers
■ M&E tools: - (print-out)
■ Infrared thermometer
■ PPEs supplies (face mask, sanitizer, etc.)
Participant The target audiences for this training includes EPI managers/ focal
Selection persons, nurses, health officers, midwives, and medical practitioners (it
Criteria includes all health care providers involved in the provision of

immunization services and facilitation of this course)
Trainer Health care providers, program managers involved in the development of
Selection this training package or trained health workers with basic COVID-19
Criteria vaccine and those who have experience in facilitating trainings
Participant
Method of
■ Pre/post-course evaluation
Course
■ Daily course evaluation (discussions, recaps, reflections)
Evaluation
■ Reflection from the trainers and trainees
■ Participant attendance

VI Facilitator Guide
Certification The participants need to score minimum 70% in post-course assessment and
Criteria 100% attendance
Course 2 Days
Duration
Suggested Approximately 25-30 participants, with a trainer to trainee ratio of 1: 5-8
Class Size
Convenient enough to accommodate participants and to conduct group
Training
exercises, role play/demonstrations, and presentations, well-ventilated
Venue
and lighted, allow physical distancing, and PPE supplies available
■ This training will be delivered in accredited IST centers

VII Facilitator Guide
Course Agenda

VIII Facilitator Guide
Session I
Basic facts on COVID-19 Pandemic
Session duration:20 minutes Training Methods
Session description: The session ■ Session introduction
discusses the natural features of COVID- ■ Self/group reading
19 diseases and describes their mode of ■
Brainstorming, and
transmission, clinical features, ■
Discussion
epidemiological background, and ■
Summary by facilitators
prevention and control of the disease M aterials Required
pandemic.
■ Participant manual
■ PowerPoint presentation
For covid-19 disease the following
F acilitator Task
information is provided:
■ Advance preparation for the session and
■ What the disease
updated information on the disease
■ How it is spread
epidemiology,
■ The signs and symptoms
■ Read training material in advance
■ The complications
■ Manage time according to the lesson
■ Management and prevention
plan
By the end of the session, participants
■ Summarize key points after each session
will be able to:
Session Topics
■ Understand the basic facts about the ■ Introduction to COVID-19 disease
SARS-CoV-2 disease ■ Mode of transmission of COVID-19
■ Describe the COVID-19 global and disease
National Epidemiology ■
COVID-19 illness clinical presentation
■ Understand the new nomenclature for ■ COVID-19 disease epidemiology global,
different variants African, and Ethiopia
■ Explain the comprehensive prevention ■ Comprehensive prevention and
and control of the COVID- 19 pandemic control of COVID-19 disease

1 Facilitator Guide
Introduction to COVID-19 disease
Brainstorming
■ What do you know about COVID-19 disease?
■ What do you know about methods of prevention?
Conclude the session by responding to the above Comprehensive prevention and

questions control of COVID-19 disease :
Coronaviruses are a large family of viruses that The best way to prevent and slow down the
may cause illness in animals or humans. In transmission of COVID-19 is to be well-informed
humans, several coronaviruses are known to about the COVID-19 virus, the disease it causes,
cause respiratory infections with symptoms and how it spreads, through protecting against
ranging from the common cold to more severe infection by washing your hands or using an
diseases such as Middle East Respiratory alcohol-based rub frequently, not touching your
Syndrome (MERS) and severe acute respiratory face, and keeping physical distancing and
syndrome (SARS). The most recently discovered covering the nose and mouth. Vaccines are one
coronavirus, a severe acute respiratory syndrome critical tool in preventing COVID-19- related
coronavirus 2 (SARS-CoV-2), causes coronavirus illness. Generally, to prevent and to slow the
disease 2019 (COVID-19). COVID-19 was unknown transmission of COVID-19, the following practices
prior to the outbreak in Wuhan, China, in are necessary :
December 2019, but is now a pandemic affecting
■ Vaccination against the COVID-19 virus
most countries globally. The epidemiology of
■ Wash your hands regularly with soap and
COVID-19 is changing rapidly. As of October 28,
water or clean them with alcohol-based
2022, globally, the total confirmed cases of
hand rub.
COVID-19 reached over 625 million and above 6.5 ■ Maintain at least a 1-meter distance between
million deaths. The first COVID-19 case in Ethiopia
you and people coughing or sneezing.
was reported on 13th March 2020. Subsequently,
■ Cover your mouth and nose when coughing
the government declared a five-month state of
or sneezing.
emergency in April 2020. As of October 28, 2022,
■ Stay home if you feel unwell.
Ethiopia reported 493,905 confirmed cases of
■ Practice physical distancing by avoiding
COVID-19 and 7,572 deaths (CFR 1.53%).
unnecessary travel and staying away from
large groups of people.
2 COVID-19 Vaccination Training

Facilitator Guide
Facilitator Guide
Session II
Rationale and objectives for
COVID-19 Vaccine
Session duration: 10 minutes
Session description: This session aims
to provide facts on the rationale and
objectives of the COVID-19 vaccine
introduction in Ethiopia.
Learning objectives
By the end of the session, participants will
be able to:
■ Describe the rationale for COVID-19
vaccine introduction in Ethiopia
■ Explain the objectives for the COVID-
19 vaccine introduction in Ethiopia
Facilitator task:
■ Introduce the session, learning
objectives, methodology, and session
reading,
■ Assess participants understanding of
the rationale and objective of the
COVID-19 vaccine introduction

Facilitator Guide
Session III
COVID-19 Vaccine supply
chain and waste management
Session duration : 155 minutes
About session
Training methods
This session describes the current global ■ Brainstorming
development on the COVID-19 vaccines, WHO ■ Lecturette Videos
EUL vaccines, forecasting and procurement, ■ Reading,
vaccine storage, handling, and cold chain ■ discussion
management and stock management, and ■ Exercises
waste management. Facilitator preparation

Learning objectives ■ First, carefully read the detailed lesson
The primary objective of this session is to plan and understand the activities very
describe the current global development well
status on COVID-19 Vaccines and their ■ Read session 6 of the participant
logistic and supply chain management. By manual and other references
the end of this session, participants will be ■ Read the PowerPoint presentation
able to: ■ Collect and prepare all necessary
■ Describe the COVID-19 vaccine landscape
training materials and job aids in
■ Describe WHO EUL COVID-19 vaccines and
advance of the session
their characteristics
Materials and Training Aids
■ Explain how to forecast the COVID-19
■ Adequate number of Participant manuals,
vaccine and associated supplies
■ Facilitator guide, LCD, Laptop computer
■ Describe COVID-19 vaccine stock
■ Pfizer vaccine preparation for
management and distribution
administration video
■ Describe the storage and handling of
■ Flip charts and markers
COVID-19 vaccines
■ Describe the Management of waste
associated with COVID-19 vaccination

Facilitator Guide
Sessions of the modules
To make the facilitation of this module hands-on, the module has

been conventionally divided into four parts.
Remark
COVID-19 Vaccine landscape and WHO Emergency

Use List Vaccines (10 minutes)
■ Display the learning objectives power ■ Ask the Participant to read sessions 3.1
point and 3.2 of the participant manual
■ Display brainstorming questions and ask Display and discuss the COVID-19 vaccines
two volunteers to answer ■ landscape from the power point.

Facilitator Guide
COVID-19 VACCINE Currently Used
in Ethiopia (60 minutes)
■ Divide the participants into four groups ■ Read your participant manual for 30
■ Assign each group secretary and group minutes Prepare summary report
leader onCOVID-19 Vaccine
■
For group 1 - AstraZeneca ■ Type Target age group,
■
For group 2-Janssen Characteristics, Route, Formulation,
■
For group 3 - Pfizer Presentation, Dosage, Number of
■
For group 4- Sinopharm doses, Schedule, Handling
procedures, Storage temperature and
Precautions and Recommendations
for All EUL Vaccine Types Shelf life
(10 minutes) ■ The group leader presents the
summary report to the large group
■ Ask participants to read their manuals
within 5 minutes
from, session 3.3 for 10 minutes ■ Thank all presenters
■ Then display the summary ppt of session
Cold chain equipment requirement
3.3 and discuss it for 10 minutes
for COVID-19 Vaccines
■ Ask participants if they have any
(20 minutes)
questions and entertain them
■ Display brainstorming questions and ask
accordingly
volunteers to answer
COVID-19 Vaccine handling, ■ Write down their answers on a flip chart
storage, and stock management
(20 minutes) Ask participants to read their manuals
from session 3.4 for 5 minutes
■ Display brainstorming questions and ask
■ Display the summary ppt of this topic
volunteers to answer
and discuss for 5 minutes
■ Write down their answers on flip chart
■ Answer the brainstorming questions
and discuss for 5 minutes

Facilitator Guide
Forecasting & Procurement of
COVID-19 Vaccine & Supplies
(20 minutes) Answer
■ Display the Ppt on forecasting and A. Target Population
procurement of COVID-19 vaccines and =3,000,000*0.7=2,100,000
give general summary Vaccine requirement =Target
■ Divide participants in to four groups Population*Number of does* wastage
and allow them to do the exercise for 10 factor.
minutes =2,100,000 X 2doses X 1.11=4,662,000
■ Ask one volunteer from two group to B. Syringe requirement =Target
present the answers of one of the Population*Number of does* wastage
questions. factor.
■ Demonstrate the exercise on the flip =2,100,000 X 2doses X 1.05=4,410,000
chart and let them compare with their C. Safety boxes
answers. = (total number of syringes/100) *WF
Exercise = (4,410,000/100) *1.05=46,305
Adama City has a population of 3 million and

COVID-19 Vaccine Stock
management and distribution
plans to vaccinate 70 % of the population in
the coming year. The current vaccine
(10 minutes)
■ Display brainstorming questions and
portfolio data shows, most of the vaccines in
ask volunteers to answer
the pipeline are two doses per target within
■ Write down their answers on a flip
4-12 weeks intervals and the estimated
chart
vaccine wastage rate is 10% and 5% for
■ Ask participants to read their manuals
syringes and safety boxes.
from, session 6.6 pages……to …. for 10
Based on the given data: Calculate:
minutes
A. The total doses of the COVID-19 Vaccine
B. Syringes
and discuss it for 5 minutes
C. and safety boxes are required to address
the targets.

Facilitator Guide
Management of Waste Associated
with COVID-19 Vaccination
(10 minutes) Answer:
■ Display the Ppt on Waste Management of Given that: -

COVID-19 vaccines and give a general ■ Beginning balance=2,500 Doses
summary…10 minutes ■ Total received=3,000 Doses
■ Ask participants to do the exercise on ■ Total Administered does=2,670
Wastage Calculation for 5 minutes ■ Remaining Balance=1,100 Doses
■ Ask one volunteer to answer the Wastage

A. Calculate the AZ Wastage rate:
exercise on a flipchart for 5 minutes
Number of doses discarded x 100
■ Cross-check the answers and
Wastage rate = Start balance + received
demonstrate the Exercise on the flipchart
Discarded Dose=BB + Received-Administered-
■ Thank the Volunteer and Display the
Remaining Balance
Session summary 5minutes
=2,500+3,000-2,670-1,100=1,730
■ Ask Participants for any clarity questions
Wastage rate=31%
……….5minutes
Wastage factor=100/69=1.45
Example 4
Wastage rate Calculation Exercise

Bole Health Centre received 3000 doses of
the AstraZeneca vaccine in 10-dose vials
and about 2,670 individuals were
immunized 1st dose and about 1,950
individuals were immunized 2nd dose and
650 were immunized to a booster dose.
There was a start balance of 2,500 doses
leftover from previous Covid 19 Campaigns.
Currently, the AstraZeneca Physical count is
1100 doses.
A. Calculate the AZ Wastage rate
B. Calculate the Wastage Factor.

Facilitator Guide
Session IV
Adverse Events following
immunization (AEFI) Surveillance
Session duration: 90 minutes
■ Explain how to prevent the occurrence of
Session description: This session
ALFI
Describes concepts of Adverse Events
■ Detect, manage and report COVID-19
Following Immunization (AEFIs) monitoring
vaccines related AEFIs
for COVID-19 to enable the participants to
■ Explain the importance of COVID-19
acquire the necessary knowledge and skills
vaccine safety monitoring and response
to monitor and manage AEFIs.
Session Outline
Learning objectives
■ Definition and categories of AEFI
By the end of this session the participants
■ Covid-19 vaccine related AEFI
will be able to;
■ Prevention and management of AEFIAEFI
■ Define Adverse Events Following ■ surveillance, detection, reporting, the
Immunization
investigation, and communication
■ Differentiate serious and minor AEFI
■ Summary
Describe the five categories of AEFIs
Summary of Activity
Slide
S. No Session Method of delivery Duration Material
number
Introduction to the
1 PPT presentation 5 Minutes
session
■ Computer
Interactive
■ LCD projector
Definition and lecture with PPT
2 20 Minutes ■ Flip chart
categories of AEFI presentation,
group exercise ■ Plaster
■ Marker
Interactive
COVID 19
3 lecture with PPT 15 Minutes
vaccine related
presentation
AEFI

Facilitator Guide
Slide
S. No Session Method of delivery Duration Material
number
Interactive
Prevention and lecture with PPT
4 management of presentation, 20 Minutes
AEFI brainstorming
case study
AEFI surveillance,
detection, Interactive
5 reporting, lecture with PPT 30 Minutes
investigation, and presentation
communication
Interactive
6 Summary lecture with PPT 5 Minutes
presentation
Preparation before session Session 4.2: Definition and

■ Read the participant manual, facilitator categories of AEFI
guide the PowerPoints and other ■ Start the presentation by defining the
reference materials AEFI by displaying the PPT slide
■ Prepare brainstorming ideas before the ■ Describe the categories of AEFI
presentation ■ Display summarized categories of AEFI
table XX
Session 4.1: Introduction to
■ Display the below table and follow the
Session
participants to assess themselves by
In 2 minutes, introduce the description,
matching the listed AEFI following
outline, and objectives of the session by
COVID-19 vaccination with the likely
displaying them on the PowerPoint
causality categories

Facilitator Guide
AEFIs following COVID-19 vaccination
Likely Causality Category
(hypothetical)
Sweating and palpitations in an HCW following A. Vaccine product-related reaction (As per
Covid-19 vaccination published literature)
Febrile seizure one- post-AZ vaccination in a

B. Immunization anxiety-related reaction
patient diagnosed with severe malaria.
Sudden onset of generalized purpura,

petechiae, and ecchymosis in a 45-year-old,
C. Underlying or emerging condition(s),
Female accompanied by severe abdominal
or condition(s) caused by exposure to
pain, elevated D-dimer levels. Death one
something other than vaccines.
week after vaccination. Mesenteric venous
thrombosis on autopsy.
■ Answer: 1.B, 2.C, 3.A Session 4.4: Prevention and

Session 4.3: COVID-19 Vaccine Management of AEFI
related AEFI ■ Brainstorming on how to prevent and
manage AEFI.
■ Present slide and describe the known
■ Display slide and summarize the general
COVID-19 vaccines related to AEFI.
■ Instruct to read the reports on the clinical principles on prevention and management
of AEFI focusing on immunization error-
trial and post-authorization use from the
related reactions.
training manual on page xx to understand
■ Display slide and tell participants the key
frequently reported systemic reactions for
features of anaphylaxis and how to
specific COVID-19 vaccines.
differentiate it from syncope and fainting.
■ Proceed to slide number XX and in two
minutes ask two participants to respond

to how to manage the case
presented.

Facilitator Guide
Case Study: 5.1
A 30-year-old female from Jimma town took the Janssen C-19
Time: vaccine (First dose) around 10:00 in the morning. After 20 minutes of vaccination, she
5 minutes started to manifest wheezing, shortness of breath, uvular swelling along with tachycardia
(PR=122 beats/min) and hypotension (Blood pressure of 80/50mmHg), epigastric pain,
high- grade fever, headache, myalgia, chest pain, itching, cramping type
of abdominal pain and rash starting from lower extremities which progressively involved
all over the body.
Answer to the case study 5.1(Question ■ Print and distribute reporting formats to
number 1 and 2) participants/groups

1. Anaphylaxis ■ Based on the
2. Adrenaline (1:1000) preparation, IV fluids Case study 4.6: Ask the participants
preferably Normal Saline (NS) at least three bags,
to answer question number 3,4 and 5.
IV cannula, Syringe with a needle, Plaster, BP
Answer to Case Study 5.1 (for question
cuff,
number 3&5)
(3) The vaccinator should be reported to Jimma
Session 4.5: AEFI surveillance,
health center
detection, reporting, investigation,
(4) Reportable variable: Name, Address, sex, age,
and communication
reporter name, Vaccine name and expire date, batch
■ Ask the participants to define AEFI number, date and time of vaccination, dose,
surveillance? Description of the AEFI, date of AEFI onset,

■ Summarize participant’s reflections and seriousness, outcome
present the standard definition of AEFI Available variable: Age, sex, vaccine name,
surveillance and its objective time of vaccination, the onset of AEFI, and
■ Provide a sticky notepad for participants description
/groups and ask them to write down the (5) Invite two groups to present the completed
components of the AEFI surveillance cycle. and report form and discuss it
post on the classroom wall sequentially to Session 5: Summary

■ Take 5 minutes and summarize key points
■ make a full cycle of sticky notes.
Present the correct AEFI surveillance of the session using the PPT slide number
cycle and move to the next slide XX
■ Present slide and briefly describe the ■ Invite to ask any unclear questions
detection, notification, and reporting

Facilitator Guide
Session V
DEMAND GENERATION/
PROMOTION & RISK
COMMUNICATION
Total time allocated: 150 minutes Session Outline
Primary Objective ■ Introduction to communication/demand
By the end of this session, participants will be generation
able to describe the effective communication ■ Demand generation/promotion strategies
methods, demand promotion strategies and for Covid-19 vaccination
approaches, and Risk and Crisis communication ■ Demand generation/promotion
for successful COVID- 19 vaccine implementation. approaches for Covid-19 vaccination

Advance
Enabling Objective
■ Risk/crisis communication about COVID-
■ After completing this session, participants
19 vaccines
will be able to:
Material
■ Describe the importance of communication for
■ Flip Chart and Markers
the COVID-19 vaccine implementation
■ LCD Projector and Laptop
■ Describe and identify COVID -19 vaccine
■ Participant manual
demand promotion strategies and approaches
■ Trainer’s guide
Identify the target audience for advocacy,
social mobilization, program communication,
Training Methods
and risk/crisis communication for the COVID- ■ Brainstorming
19 vaccine implementation ■ Session introduction using PPT

■ Develop skills to effectively communicate with ■ Discussion and plenary session
community members and stakeholders about ■ Group activities: Role plays and group works
the COVID-19 vaccination, Introduce the session to participants and
■ Promote the acceptance of COVID-19 vaccines explain the learning objectives using power
and other routine immunization among the point or flipchart
communities.

Facilitator Guide
Facilitator Preparation
■ Carefully read the detailed lesson plan and understand the activities very well
■ Read session 5 of the participant manual and other references
■ Read the PowerPoint presentation
■ Collect and prepare all necessary training materials and job aids in advance of the session
■ Prepare necessary information on a flip chart (if LCD is not applicable)
ppt Slide
S.No Activity Methdod of Delivery Time
No.
Basics of Communication Brainstorming (5 min) and

1 and demand promotion demand promotion 20 Minute
Interactive presentation (15
min)
Demand Brainstorming (5 min) and
2
generation/promotion demand promotion
strategies on Covid-19 20 Minute
vaccination min)
Demand Brainstorming (5 min)
3 generation/promotion Interactive presentation
approaches on Covid-19 (20 min) 60 Minute
vaccination Group activity/Role play
(40 min)
Risk/crisis Brainstorming (10 min)

4
communication on Covid- Interactive presentation
19 vaccination (20 min) 50 Minute
Group activity and
discussion (20 min)

Facilitator Guide
5.1. Basic of Communication and 5.2. Demand Generation
Demand promotion /Promotion Strategies
Allocated time: 20 minute Allocated time: 20 minute

■ Tell the participants to read session 5.1 of the Start the topic by asking about demand
participant’s manual on basics of generation/promotion strategies and raise the
communication and ask the following following brainstorming questions and allow
brainstorming questions and discussing them. the participants to discuss them.
■ What is communication? ■ What are the major demand generation /
■ What are the principles of effective communication strategies?
communication? Summarize the reflections of the participants
■ Based on the reflections of the participants and provide a general overview of the three
summarize the basic concept major demand generation/promotion
of communication and principles of effective strategies in Covid-
communication 19 vaccination.
■ Allow participants to ask questions as well 5.3. Demand Generation Approach
as to add more points Allocated time: 60 minute
■ Entertain the questions raised and summarize start the topic by asking the following
the session and proceed to the Communication
brainstorming questions and discussing
gaps on Covid-19 vaccines Brainstorm the
them. (5 minutes)
participants by asking the ■ Mention the major demand
following question
generation/promotion approaches used
■ What are the major communication
to achieve high acceptance and uptake of
gaps on the Covid-19 vaccine that you
COVID-19 vaccines.
encountered during the implementation
Based on the reflections of the participants,
of Covid-19 vaccination?
present and discuss, especially the main types
■ Allow the participants to discuss and list
of communication interactions that occur
out the major communication gaps in
within a provider-client relationship and key
Covid-19 vaccine uptake
elements of interpersonal combination/IPC/.
Summarize the session by addressing the
main communication gaps on the Covid-
19 vaccine

Facilitator Guide
Case scenario on interpersonal
communication
■ Divide the participants into four groups Based on the reflections of the participants,
■ Allow the participants to read the case scenario present and discuss on risk, risk communication,
for 5 minutes from the participant manual crisis, crisis communication and reasons for
■ Provide adequate time for role play (15 crisis in immunization program including Covid-
min) 19 vaccine.
■ Select two groups and invite them to Group Work
demonstrate the role play (5 minutes for ■ Explain to the participants to discuss with
each group) their side mates the group work (three
■ After the end of both roles, plays ask participants in each team)
participants: (5 minutes) ■ Present the group work questions (5 minutes)
Q.1: “Does the health care worker communicate The Questions are:
to the mother and student 1. What kind of crisis occurred during the
clearly and effectively?” last Covid-19 vaccination rollout/
Q.2: What information the health worker shared campaigns in your area/region? (May be
with the mother and student? Was related to AEFI or other conditions)
it helpful? How would you do things differently? 2. What measures were taken to manage the
Q.3. Do you come across such challenges? incident?
How you have addressed such an issue? 3. Who engaged in the response?
Final reflection on the role play (5 min) ■ Provide adequate time for the group work
■ Present the PowerPoint on demand (5 min)
generation/ promotion approaches and ■ Select five teams to present (2 minutes
summarize the session. (15 minutes) for each group)
5.4. Risk and crisis communication Final reflection on the group work (5 min)
Allocated time: 20 minute Present the PowerPoint to the management
Start the topic by asking the following of risk/crisis and summarize the session.
(20 minutes)
brainstorming questions and discussing it. (5
minutes)
■ What is risk and risk communication?
■ What is a crisis and crisis communication?

Facilitator Guide
Session VI
Coordination and planning for
COVID-19 Vaccine
Session duration : 90 minutes
■ Explain the required coordination
Primary objectives mechanisms for COVID-19 vaccine rollout
By the end of this session participants will ■ Describe the COVID-19 vaccine rollout
be able to describe the overall COVID-19 micro-planning and preparation process
vaccine rollout planning and coordination ■ Outline the important planning
mechanism components for the COVID-19 vaccine

rollout
Enabling objectives
After completing this session, the
participants will be able to:
PPP
Activity Method of delivery Time
slide No.
COVID-19 vaccination
Interactive presentation 20 minutes 6
coordination mechanism
Brainstorming (10 min)

Micro-plan development
Interactive presentation (20 min) 70 minutes 7-17
process
Group activity and discussion (60 min)
Materials
■ Flip Chart and Markers LCD
■ Projector and Laptop Participant
■ Manual Trainer’s guide
■ Print out MP template

Facilitator Guide
Activity 1: COVID-19 vaccination coordination mechanism
■ Ask general question about the existence of coordination
mechanism in the area (Give chance to 2 person)
■ Encourage participants to respond
■ Present the power points and discuss on the coordination
mechanism
Activity 2: Micro-plan development process
■ The facilitator will ask the brainstorming question to the
participants & allow them to respond.

■ Present the power points and discuss the Micro-plan development
process
Micro-planning group exercise

■ Divide the participants into five groups and give the MP template
for each group

■ Allow the participants to read the case scenario for 5 min from
the participant manual.

■ Provide adequate time for group discussion 20 min
■ Group presentation for each group to present (5 min each group)
■ Help them to use flip chart
■ Final reflection (10 min)

Facilitator Guide
Session VII
Vaccine delivery strategies
Session duration: 120 minutes Enabling objectives
Primary Objective By the end of the session, participants will

be able to :
By the end of this session participants will
■ Identify vaccine delivery strategies for
be able to describe the COVID 19 vaccination
the different priority groups
delivery strategies and organizing
■ Outline how to organize COVID-19
vaccination sessions.
vaccination sessions
■ Demonstrate COVID-19 vaccine
Summary of activities
administration
Activity Method of delivery Time Slide No.
Think, Pair & Share (10 min)

Vaccine delivery strategies 35 minutes
Interactive presentation (25 min)
Group activity and discussion (15 min)

Organizing COVID-19
35 minutes
vaccine session Interactive presentation (20 min)

Vaccine administration 50 min
min) Demonstration (30 Min)
Materials
■ Flip Chart and Markers ■ Demonstration materials
■ LCD Projector and Laptop ■ Doll/Sponge/orange
■ Participant manual, Trainer’s guide ■ Vaccine & Syringe, Safety box , Glove

Facilitator Guide
Activity 1: Vaccine delivery
strategies
■ Ask the participant to be paired, discuss
on the general question, and reflect

about the vaccine delivery strategies
■ Encourage participants to respond
■ Present the power points and discuss on
the coordination mechanism
Activity 2: Organizing COVID-19

vaccine session
■ The facilitator will ask the participant to
discuss with the closer person and allow
them to respond.
■ Present the power points and discuss on
how to organize COVID-19 vaccine
COVID 19
session.
Vaccine
Vaccine administration
■ Present the power point presentation

■ Divide the participants into five groups
and give demonstration materials for

each group
■ Allow the participants to demonstrate

vaccine administration.
■ Final reflection

Facilitator Guide
Session VIII
Monitoring and evaluation of
COVID-19 Vaccination Session Outline:
Session duration: 180 minutes ■ Introduction to the COVID-19 vaccine
Session description: monitoring
This session describes the importance of
■ Indicators to monitor COVID-19
monitoring and evaluation during the COVID-
vaccination progress
19 vaccine introduction to enable the
■ COVID-19 Vaccination Monitoring Tools
participants to acquire the necessary
■ COVID-19 Vaccination campaign
knowledge, skills, and attitude to monitoring
monitoring
and evaluation of the COVID-19 vaccine
■ Evaluation of COVID-19 vaccine rollout
introduction. This section also discusses the
major monitoring indicators and tools to be
used during the COVID-19 vaccine
introduction.
Learning Objective:
■ By the end of this session, the
participants will be able to:
■ Describe monitoring and evaluation
approaches to COVID-19 vaccination
■ Explain and use the set indicators for
COVID 19 vaccine monitoring
■ Describe and use COVID-19 vaccination
campaign monitoring system
■ Identify and use the COVID-19 vaccine
monitoring and evaluation tools

22 Facilitator Guide
S.no Session Method of Delivery Duration Material
1. Introduction to the 5 Minutes
PPT Presentation
session
■ Computer
2 Introduction to the 20 Minutes
Brainstorming activity
■ LCD projector
COVID-19 Vaccine
PT presentation
■ Flip chart
40 Minutes
3 Indicators to COVID- monitor PPT presentation ■ Plaster
19 vaccination Group Exercises (case ■ Marker
progress studies)
■ Participant
manual
COVID-19 65 minutes
4 ■ COVID-19 vaccination
monitor
vaccination recording and
PPT presentation
monitoring tool reporting tools
Group Exercises (case ■ COVID-19 vaccination
studies) data management
SOP
COVID-19 Vaccination Interactive lecture with 15 minutes
5
campaign monitoring PPT presentation,
brainstorm case
6 Review Meeting PPT presentation 5 minutes
Supportive PPT presentation 5 minutes
7
supervision
Evaluation of Interactive lecture with 15 Minutes

8 COVID-19 vaccine PPT presentation
rollout
9 Summary PPT presentation 10 Minutes 10 Minutes

Question and answer
Preparation by the facilitator for this session:
■ Read Session 8 (monitoring and evaluation of COVID-19 vaccination session) of the

participant manual, power points, facilitator guide, and other reference materials
■ Prepare a lesson plan and training materials for practical exercise with a case scenario
■ Prepare brainstorming ideas before the presentation
■ Learning method: Plenary presentation, individual /group reading, group

discussion/exercise,

23 Facilitator Guide
8.1.Introduction to COVID-19 8.2.Indicators to monitor COVID-19
vaccine monitoring vaccination progress
Allocated time: 20 minutes Allocated time: 60 minutes
■ Tell the participants to read session 8.1 of the
■ Tell the participants to read session 8.2
participant's manual on introduction to COVID- of the participant's manual on indicators to
19 vaccine monitoring and ask the following monitor COVID-19 vaccination progress and
brainstorming questions and discuss it. raise the following brainstorming questions
■ What is monitoring? and allow the participants to discuss it.
■ Why do we monitor COVID-19 ■ What is Indicator?
vaccination? ■ Which COVID-19vaccination indicator
■ Based on the reflections of the participants do you know?
summarize the basic concept of monitoring Summarize the reflections of the participants
and why COVID-19 vaccination monitoring is and provide a general overview of the COVID-
important. 19 vaccination indicators.
■ Allow participants to ask questions as well, as
Vaccine uptake and coverage
to add more points.
monitoring
■ Entertain the questions raised and summarize
■ Ask participants about the difference
the session and proceed to the COVID-19
between uptake and Coverage. Explain the
vaccination monitoring system.
difference with an example
■ Brainstorm the participants by asking the
■ Summarize and explain the core COVID- 19
following question
coverage indicators and their data sources.
Do you know any COVID-19 vaccination Proceed to the COVID-19 vaccine supply
monitoring systems?
indicators.
Allow the participants to discuss and list out
the approaches to monitoring COVID- 19
Vaccine supply and logistic indicators
vaccination. Start the sub-session by raising the following
Summarize the session addressing the main brainstorming questions and allow the
monitoring approaches participants to discuss it
■ How do you calculate Vaccine wastage

rate?
Summarize the reflections of the participants

and explain the core vaccine supply
indicators and their data sources.

Facilitator Guide
Demand promotion and communication
indicators
Raise the following brainstorming questions and ■ Organize the participants in a group
allow the participants to discuss them. Support groups to undertake the exercise
■ What is the importance of monitoring ■ Tell the participants to read the group
demand promotion and communication exercise questions from the participants
indicators? manual
Summarize the reflections of the participants ■ Summarize and discuss the answers with
and provide the general overview about the participants
core demand promotion and communication Allow participants to raise questions or
indicators with their data sources additional points
Answer:
Vaccine Safety (AEFI) Monitoring and
Surveillance Indicators 1. 15000 doses administered
2. 9000 individual completed the primary series
Start the sub-session by raising the following
3. Vaccine uti.rate= 15000/(2000-4600)*100=97%
brainstorming questions and allow the
Vaccine wastage rate=100-97=23%
participants to discuss over it
Vaccine Wastage Factor=100/100-23=1.3%
■ What is the importance of monitoring
AEFI indicators? 8.3.COVID-19 Vaccination
■ Which AEFI indicators do you know? monitoring Tools
■ How do you monitor COVID-19 morbidity Allocated time: 90 minutes
and mortality? Tell the participants to read session 8.3 of the
Summarize the reflections of the participants
participants' manual on COVID-19 vaccination
and provide a general overview of the core AEFI
monitoring tools and ask the following
and COVID-19 surveillance indicators with their
brainstorming questions and discuss them.
data sources ■ What should we consider in recording and
Planning, coordination, related reporting COVID-19 vaccination data?
Indicators and system
Based on the reflections of the participants
Explain the importance of monitoring planning
summarize the basic data collection and
coordination and system related indicators to the
reporting principles of COVID-19
participants
vaccination
Summarize the session by explaining core
Allow participants to ask questions as well as
planning, coordination, and system related
to add more points.
indicators
Entertain the questions raised and summarize
Group Exercise
the session and proceed to the COVID-19
vaccination recording tools

Facilitator Guide
8.3.2.COVID-19 Vaccination register
Notes to the facilitator ■ Explain the importance of the COVID-19
vaccination register, who updates the
■ Every vaccination is given at any visit will
register, where to keep the register, and
be recorded/updated in the COVID-19
when to use the vaccination card
vaccination register and COVID-19
■ Discuss the steps to be used to complete the
vaccination card
COVID-19 vaccination card
■ All vaccination given will be tallied based
■ Discuss the procedures for using the COVID-
on the appropriate disaggregation (Age
19 vaccination register
group, Gender, Dose, special population
■ Read and explain the participant manual on
group, and vaccine type)
how to record information in the register
■ Vaccination data will be aggregated daily
and explain each data element in the
and reported to the next level
register
■ Data should be entered into DHIS2
COVID-19 vaccination reporting the
system at the Woreda level Notes to the facilitator
■ For every new person (never
vaccinated) create a new entry
Start the topic by brainstorming question
in the register and create a new
■ List and explain the recording and COVID-19 vaccination card
reporting tools used for COVID-19 ■ In subsequent visits locate the
vaccination. individual’s entry by Serial Number
Based on the reflections of the participants or ID number in the register and
summarize the main recording and reporting update data for each dose provided
tools for COVID-19 vaccination. ■ Doses administered should be
recorded legibly in the vaccination
8.3.1. COVID-19 vaccination card register immediately after
■ Explain the importance of the COVID-19 administration of the vaccine (and
not before or much later)
vaccination card, who updates the card,
■ There should be a unique
where to keep the card, and when to use
identification number (serial
the vaccination card number or ID number) on the
■ Discuss the steps to be used to complete register for each individual and use
the COVID-19 vaccination card the same number on the COVID-19
vaccination card. This way, for the
■ Read and explain the data elements in
next vaccination, it will be very easy
the vaccination card
to locate the individual’s entry on
the register

Facilitator Guide
8.3.3. COVID-19 vaccination ■ Explain the contents of the daily reporting
format
Tally sheet
■ Read and explain the participant manual on
Start the topic by raising the following
how to record information in the register and
brainstorming questions
explain each data element in the register.
■ What is the purpose of the tally sheet?
■ When should we tally COVID-19 8.3.5.DHIS2 aggregate reporting
vaccination data? module
Based on the reflections of the participants ■ Explain to the participants about DHIS2
summarize the use of the tally sheet, when aggregate reporting module
who updates the tally sheet. ■ Emphasize that DHIS2 is the primary
Explain the procedures for tallying COVID-19 reporting tool for COVID-19 vaccination
vaccination data data
■ Inform participants that, aggregated data
Notes to the facilitator from each vaccination site will be compiled
■ Tally ALL vaccinations are given to and entered into DHIS2
ALL populations including special on daily basis
population groups by age and sex
disaggregation, then Tally the number 8.4.COVID-19 Vaccination campaign
of special population groups (Health monitoring
workers, IDPs, refugees, people with Start the topic by forwarding the following
disability, and people with a medical
brainstorming questions
condition) vaccinated out of the total
■ What makes mass campaign vaccination from
vaccination
■ Doses administered should be routine vaccination?
tallied immediately after ■ When should we monitor campaigns?
administration (and not before or Based on the reflections of the participants
much later)
summarize the importance of the COVID-19
vaccination campaign monitoring
8.3.4. COVID-19 vaccination daily Explain to the participants the different phases of
reporting forms COVID-19 vaccination campaigns
■ Explain to the participants the importance of monitoring
the COVID-19 vaccination daily reporting ■ Pre-campaign phase monitoring activities
format and the data flow ■ Intra Campaign phase monitoring activities
■ Discuss the steps to be used to complete and ■ Post Campaign phase monitoring activities
submit daily vaccination report
27
8.5.Review meetings (5 minutes)
Explain the importance and procedures of review ■ The COVID-19 vaccination monitoring
meetings in COVID-19 vaccination monitoring system is designed to measure equitable
uptake and coverage over time by
8.6.Supportive Supervision geography, and high-risk population
(5minutes) groups
Explain the importance and procedures of ■ Administrative reports, supportive
supervisions, review meetings, and
supportive supervision in COVID-19 vaccination
surveys are the main monitoring and
monitoring
evaluation systems for COVID-19
8.7.Evaluation of COVID-19 vaccine vaccination
■ Vaccination cards, immunization
rollout (15 minutes)
registers, tally sheets, AEFI forms, daily
Start the topic by forwarding brainstorming
reporting formats, and the DHIS2 system
question is the main recording and reporting tools
■ What is Evaluation? What makes it for COVID-19 vaccination monitoring
different from Monitoring?
■ Every single vaccination data should
Explain and discuss the evaluation activities in
be recorded in the COVID-19 registration
book, and tally sheet and reported
COVID-19 vaccination evaluation Summarize the
through the daily reporting form and
M&E session by reminding the following points DHIS2
(10 minutes) ■ The COVID-19 vaccination campaign
should be monitored during the pre-
campaign, intra-campaign, and post-
campaign phases
■ Core coverage, demand promotion,
vaccine logistics, AEFI, surveillance, and
other system-related indicators should
be analyzed and interpreted on a regular
basis for timely and evidence-based
decision-making.

Facilitator Guide
Annex: 1 Course Assessment questions
1. Which of the following methods is not effective for the reduction in the transmission of COVID-19
disease?
A.Vaccination
B.Wearing masks
C.Prophylaxis with anti-viral medication
D.Physical distancing
2. Eradication of the COVID-19 virus is the main rationale behind the introduction of COVID-19 vaccines?
A.True
B.False
3. Intra-sectoral and multi-sectoral coordination mechanism is crucial for COVID-19 vaccination rollout
at all levels of the health system.
A.True
B.False
4. Which one of the following is not the key consideration to conducting a Kebele-level micro plan?
A.Target population
B.Cold chain inventory
C.Identifying service delivery strategies
D.Developing operational map
E.Knowing the target population of the neighboring Kebele
5. Kebele ‘’X ‘’ has a total population of 10,500 from this, 1,500 targets received Astra Zeneca's first dose
and 825 targets completed the primary vaccination series. Kebele ‘’X’’ has the plan to vaccinate the
target population through the campaign. What would be the total target for 1st, the 2nd, and Booster
doses respectively? Use this conversion factor =62.3 %.
A. 6510,825,675
B. 6615,675,825
C. 5042,675,825
D. 6563, 825,675
6. Which of the following service delivery strategies is not more applicable for hard-to-reach/hard-to-
serve areas/communities?
A.Static/Fixed
B.Temporary fixed
C.Outreach
D.Mobile

Facilitator Guide
7. During preparation for the vaccination session, which one of the following would not be the most
important?
A.Knowing the team composition & target for the session
B.Applying Infection prevention technique
C.Mapping of Session organization
D.None of the above
8. Which of the following are the recommended practices during COVID-19 vaccine administration?
A.Checking the expiry date of the vaccine
B.Ensure the right match for a vaccine with diluent as per the manufacturer's recommendation
C.Discard the used needle and syringe without recapping them in the safety box
D.Label each vaccine vial with the date and time immediately when opened
E.All of the above
9. Which of the following COVID-19 vaccines is an mRNA vaccine?
A.Astra Zeneca
B.Sinopharm
C.Pfizer
D.Johnson & Johnson
10. At the health facility level all COVID-19 vaccines can be stored at +2°C to +8°C, and maintain the
original shelf life indicated by the manufacturer
A.True
B.False
11. Kirkos Sub City has a population of 2 million and plans to vaccinate 67% of the population in the
coming year. The current vaccine portfolio data shows, most of the vaccines in the pipeline are two
doses per target within 4-12 weeks intervals and the estimated vaccine wastage rate is 10% and 5% for
syringes and safety boxes. Based on the given data: What would be the total doses of COVID-19 Vaccine,
syringes, and safety boxes required to address the targets?
.2,814,000 Doses, 2,977, 7782, syringes and 29,547 safety boxes
B.2,977,778 Doses, 2,814,000, syringes and 2,814 safety boxes
C.2,977,778 Doses, 2,814,000, syringes and 29,547 safety boxes
D.2,977,778 Doses, 2,814,000, syringes and 2,954 safety boxes
12. Millennium Health Centre received 2,800 doses of the Pfizer vaccine in October 2022. The coverage
report indicated that 1,200 clients were getting vaccinated with Pfizer Vaccine. There was no start
balance and by the end of October 2022, the stock level was 1,400 doses. Calculate and discuss vaccine
wastage.

Facilitator Guide
A.7%
B.3%
C.6%
D.2%
13. Which of the following is not a cause for AEFI?
A.Vaccine product-related reactions
B.Immunization anxiety-related reactions
C.Coincidental events
D.Vaccine quality defect-related reactions
E.None
A14. Which of the following is not a serious AEFI?
A.AEFI that resulted in the death
B.AEFI that resulted in minor swelling and redness at the injection site
C.AEFI that resulted in disability/incapacity
D.AEFI that resulted in hospitalization
15. Which of the following is not a cause for program error related to AEFI?
A.Nonsterile injection
B.Reconstitution error
C.Injection at incorrect site
D.Inadequate inactivation of live viruses by the manufacturer
16. One of the following is not the Role of Health Care worker in community communication on AEFI
A. Communicate immediately with the MoH and other high officials.
B. Provide the parents with information
C. Reassure parents, caregivers, and adults that necessary measures are being taken
D. Communicate the results of the investigation to the media
17. One of the following is not correct about the COVID-19 communication activities to be conducted by
HWs
A. To inform the risk of COVID-19 infection to all clients in any opportunities
B. To inform all sources of information are credible about the COVID-19 vaccine
C. To incorporate the issue of COVID-19 in the routine HF education sessions
D. To engage religious leaders and community influential to promote about COVID-19 vaccine

Facilitator Guide
18. Which of the following is not a demand generation strategy
A. Advocacy
B. Social mobilization
C. Program Communication
D. Social Listening
19. Which of the following tool is important for COVID-19 vaccination monitoring?
A. COVID-19 vaccination register
B. COVID-19 vaccination tally sheet
C. COVID-19 vaccination daily reporting form
D. All the Above
20. When should health workers tally COVID-19 vaccination data?
A. Before administering the vaccine
B. After completing the daily vaccination session
C. Immediately after administering the vaccine
D. When the opened vial is completed
21. Which of the following is an indicator for COVID-19 Vaccination Monitoring?
A. Vaccination Coverage
B. Number of people reached through media for COVID-19 Vaccination information
C. Number of Weredas completed COVID-19 vaccination micro plan
D. Vaccine Wastage Rate
E. All of the Above
Answer Key:- 1. C2. B 3. A 4. E5. C 6. A 7. D 8. E 9. C10. B 11. C 12. A13. E 14. B 15. D16. D 17. B 18. D19. D 20. C
21. E

Facilitator Guide
Covid-19 Vaccination Training
Facilitator Manual
October, 2022

COVID-19 Facilitator Guide December 1 2022

Uploaded by

Copyright:

Available Formats

COVID-19 Facilitator Guide December 1 2022

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

COVID-19 Facilitator Guide December 1 2022

Uploaded by

Copyright:

Available Formats

Federal Democratic

Covid-19 Vaccination Training

Basic Fact about the Pandemic 1

Rationale and Objective for COVID-19 Vaccine 4

COVID-19 Vaccine supply chain and waste management 5

Adverse Events following immunization (AEFI) Surveillance 10

Demand Generation/ Promotion & Risk Communication 14

Coordination and Planning for COVID-19 Vaccine 18

Vaccine Delivery Strategies 20

Monitoring and evaluation of COVID-19 Vaccination. 21 22

Course Assessment Questions 29

Participant Manual Development Team Members

Dr.Meseret Zelalem MOH Mr. Belete Alebachew MOH

Mr.Yohannes Lakew MOH Mr. Kibrom Abraham MOH

Mr.Temesgen Lemma MOH Dr. Meheret Elias MOH

Mr.Melkamu Ayalew MOH Mr. Mulat Nigus MOH

Mrs.Tewabech Alemu MOH Mr. Yosef Tariku MOH

Mr.Habtamu Alemay MOH Mr. Mengistu Bogale MOH

Mr.Sileshi Solomon MOH Mr.Meseret Adugna PPMED/MOH

Mr.Michael Sileshi MOH Mr. Agumas Kindu EPSS

Mrs.Mastewal Kerebih MOH Dr.Abayneh Girma WHO

Dr.Alemayehu Ayele MOH Mrs.Alemtsehay Berhanu GHSC_PSM

Mrs.Nafkot Abadura MOH Dr.Tedi Tilahun WHO/EFDA

Mrs.Tseganesh Gedlu MOH Dr.Adamu Gelaw WHO/EPHI

Mr.Girma Hailemariam MOH Mr.Haimanot Fisseha UNICEF

Mr.Tesfaye Bikes MOH Mrs.Selamawit Yilma WHO

Dr.Zufan Abera MOH Mr.Wondimu Ayana WHO

Mr.Tekalign Admasu MOH Mrs.Tadelech Sinamo JSI immunization

Mr.Mengesha Belay MOH Mr.Haile Kasahun AACARHB/CHAI

Mr.Jiregna Wirtu MOH Dr.Kume Alene CHAI

Mr.Biruh Tesfaye MOH Dr.Amare Bayeh PATH

Mrs.Bezawit Getachew MOH Mrs.Bethelhem Assefa MOH

Mrs.Mekdim Hailu MOH

I COVID-19 Vaccination Training

AEFI Adverse events following immunization

COVID-19 Coronavirus disease 2019

CSO Civic service Organization

DHIS2 District Health Information System

EUL Emergency Use Listing

FMOH Federal Ministry of Health

FBO Faith-Based organization

SAGE Strategic Advisory Group of Experts

SARS-COV-2 Severe Acute Respiratory Syndrome Coronavirus 2

WHO World Health Organization

COVID-19 Vaccination Training

Dr Meseret Zelalem Tadesse (MD, Pediatrician)

COVID-19 Vaccination Training

on each WHO-approved COVID-19 vaccine

through the COVAX facility and vaccines on bilateral donation

Participants After completing this course participants will be able to:

strategies and activities, and the communication process for successful

COVID-19 vaccination and explain service delivery strategies as well as

monitoring to enable the participants to acquire the necessary

EUL vaccines, forecasting and procurement, vaccine storage, handling,

process for COVID-19 vaccine introduction

COVID-19 vaccine introduction

involved during the COVID-19 vaccine at all levels.

COVID-19 Vaccination Training

Training ■ Interactive PowerPoint presentation

■ Demonstration (session organization, vaccine administration,